What is a Phase 1 Warning Letter response?

The Phase 1 response is your initial formal reply to FDA addressing each violation cited in the Warning Letter. It includes root cause analysis, immediate corrective actions taken, and a commitment to systemic corrections with timelines.

How long do I have to respond to an FDA Warning Letter?

FDA typically requests a response within 15 business days of receipt, though you can request an extension with justification. Prompt, substantive responses are critical — delays compound enforcement risk.

Can a Warning Letter affect my ability to export products?

Yes. Warning Letters are publicly posted on FDA's website and can affect import/export status, product listings, investor confidence, and customer relationships. Resolution is time-sensitive.

Book FDA Warning Letter Response Support (Phase 1)

Book FDA Warning Letter response support online. Compare vetted regulatory consultants for Phase 1 response drafting, root cause, and CAPA planning. Instant pricing.

✓ 3 active providers available right now · USD 1,472 – 1,824

Why this page is different

Instant pricing: See a price estimate immediately (no back-and-forth RFQ needed for these services).
Compare before booking: Review inclusions, exclusions, turnaround, and communication channels.
Charged only when accepted: You are charged only after a provider accepts your order and scope.
Live availability: 3 active providers available right now for this service.

What you can compare here

Total price: See live price ranges and instant pricing rules where available.
Coverage & scope: Markets served, what is included, and what is explicitly excluded.
SLA & responsiveness: Acceptance SLAs and typical turnaround windows.
Add-ons: Optional extras you can book next (shown as add-on chips).
Onboarding time: How quickly providers can start and what you need to supply.

Compare providers (instant pricing + book)

Provider	Estimated base price	Accept SLA	Turnaround	Start
Alpha Regulatory Partners	USD 1,600	24h	3–7 days	Within 2 business days
Beta Compliance Group	USD 1,824	24h	3–7 days	Within 2 business days
Gamma RegTech Solutions	USD 1,472	24h	3–7 days	Within 2 business days

Estimates are derived from each provider’s published pricing rules (and may vary by your inputs).

What affects pricing

These are the inputs providers use to price your order. Enter them once, then compare providers and book instantly.

themesCount (Required)
min 1 (count major topics/violations)
urgency (Required)
standard|urgent
desiredOutputs (Required)
min 1
buyerNotes (Optional)

⚠️

Input

FDA Warning Letter

📄

Output

Phase 1 response + CAPA plan

⏱️

Turnaround

10–25 business days

💰

Pricing

Per engagement

How it works

1

Share your FDA Warning Letter and background

Provide the Warning Letter, your previous 483 responses if any, and current QMS documentation context.
2

Compare Warning Letter response consultants

View engagement fees from regulatory consultants experienced in FDA enforcement and formal Warning Letter responses.
3

Receive your Phase 1 response draft and action plan

Your consultant drafts a formal response addressing each charge, with root cause, corrective actions, and a systemic remediation roadmap.

What is an FDA Warning Letter?

An FDA Warning Letter is a formal written communication from FDA to a regulated company or individual notifying them that the agency believes they have violated federal laws and regulations enforced by FDA. Warning Letters are publicly posted on FDA's website within 30 days of issuance. For medical device manufacturers, Warning Letters are most commonly issued when: (1) Form 483 observations from a prior inspection were not adequately addressed; (2) the Quality System Regulation (21 CFR 820) violations are systemic or recurring; (3) labelling violations constitute misbranding; or (4) a device is being marketed without required premarket clearance or approval. Unlike a 483, a Warning Letter represents FDA's formal position that violations exist.

The structure of a Warning Letter response

A Warning Letter response must address each numbered violation cited in the letter individually. FDA's established response framework requires: (1) a direct, non-defensive acknowledgement of the violation; (2) a thorough root cause analysis identifying why the violation occurred — not just what happened; (3) immediate corrective actions already taken since the inspection or Warning Letter issuance; (4) systemic corrective actions addressing the root cause across your QMS, with implementation evidence; (5) preventive actions to prevent similar violations in adjacent QMS areas; and (6) target completion dates for any actions not yet implemented. Submitting a response that simply states "we will comply" without evidence and root cause is a major error that signals to FDA that the problem is not understood.

Phase 1 vs. Phase 2 response approach

Warning Letter responses often involve a two-phase approach. Phase 1 (the initial response, typically due within 15 business days of receipt) addresses immediate corrective actions taken and provides a high-level CAPA plan with timelines for systemic corrections. Phase 2 (submitted as a follow-up, typically 30–90 days after Phase 1) provides implementation evidence for the planned corrections, including updated SOPs, training records, re-inspection results, and effectiveness checks. Phase 1 must be substantive — FDA has specifically cautioned against "superficial" initial responses. A consultant experienced with FDA enforcement can help you draft a Phase 1 response that gives FDA confidence that you understand the violations and have a credible remediation plan.

Business impact of a Warning Letter and how to mitigate it

FDA Warning Letters are published on the FDA website and indexed by Google within days. The business impact is significant: customers and distributors may invoke contract clauses triggered by regulatory action; potential acquirers or investors will see the Warning Letter in due diligence searches; online retailers and medical supply distributors may delist affected products; and import alerts can be issued blocking your products at US ports of entry. The fastest way to mitigate these impacts is to submit a substantive Phase 1 response promptly, implement corrective actions visibly, and — once FDA is satisfied — request a close-out letter. FDA close-out letters are also public and signal to the market that the issues have been resolved.

Frequently asked questions

What is a Phase 1 Warning Letter response?: The Phase 1 response is your initial formal reply to FDA addressing each violation cited in the Warning Letter. It includes root cause analysis, immediate corrective actions taken, and a commitment to systemic corrections with timelines.
How long do I have to respond to an FDA Warning Letter?: FDA typically requests a response within 15 business days of receipt, though you can request an extension with justification. Prompt, substantive responses are critical — delays compound enforcement risk.
Can a Warning Letter affect my ability to export products?: Yes. Warning Letters are publicly posted on FDA's website and can affect import/export status, product listings, investor confidence, and customer relationships. Resolution is time-sensitive.

How Cruxi Bridge vets providers

✓ Every provider submits regulatory expertise evidence and jurisdictional coverage claims
✓ Providers that go live agree to the Cruxi Bridge Provider Terms including service delivery and accuracy obligations
✓ Payment is held by Cruxi and only released to the provider after service delivery milestones
✓ Buyers can raise a dispute within 30 days — Cruxi reviews and mediates per the platform terms

Prices and provider availability are live and may change. Charged only when a provider accepts your order. ← All services